Objective: To assess whether a high-salt diet, as measured by urinary sodium concentration, is associated with faster conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) and MS activity and disability. Methods: BENEFIT was a randomized clinical trial comparing early versus delayed interferon beta-1b treatment in 465 patients with a CIS. Each patient provided a median of 14 (interquartile range 5 13-16) spot urine samples throughout the 5-year follow-up. We estimated 24-hour urine sodium excretion level at each time point using the Tanaka equations, and assessed whether sodium levels estimated from the cumulative average of the repeated measures were associated with clinical (conversion to MS, Expanded Disability Status Scale [EDSS]) and magnetic resonance imaging (MRI) outcomes. Results: Average 24-hour urine sodium levels were not associated with conversion to clinically definite MS over the 5-year follow-up (hazard ratio [HR] 5 0.91, 95% confidence interval [CI] 5 0.67-1.24 per 1g increase in estimated daily sodium intake), nor were they associated with clinical or MRI outcomes (new active lesions after 6 months: HR 5 1.05, 95% CI 5 0.97-1.13; relative change in T2 lesion volume: 20.11, 95% CI 5 20.25 to 0.04; change in EDSS: 20.01, 95% CI 5 20.09 to 0.08; relapse rate: HR 5 0.78, 95% CI 5 0.56-1.07). Results were similar in categorical analyses using quintiles. Interpretation: Our results, based on multiple assessments of urine sodium excretion over 5 years and standardized clinical and MRI follow-up, suggest that salt intake does not influence MS disease course or activity.
M ultiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disorder that likely results from a combination of genetic and environmental factors. [1] [2] [3] Recently, several in vivo and in vitro studies have suggested that salt (NaCl, sodium chloride) could potentially influence MS disease activity and progression, possibly through modulation of T-cell differentiation. 4, 5 Furthermore, mice fed a high-sodium diet developed a more aggressive course of experimental autoimmune encephalomyelitis (EAE), the animal model of MS. 4, 5 Two studies, both of pediatric MS, did not find an association of self-reported dietary sodium intake with risk of MS 6 or with relapse rate (RR) in MS patients.
patients who were followed for 2 years found that higher levels of urinary sodium excretion, a marker of dietary sodium intake, were associated with higher RRs and lesion volume. 8 However, the study was small and relied on a single spot urine sample, which is a poor predictor of average sodium intake. Furthermore, there were few relapse events, and only a cross-sectional assessment of sodium and radiographic outcomes.
We assessed longitudinally whether sodium intake, estimated from sodium excretion in multiple (median 5 14) urinary samples per subject, is associated with early MS disease activity and progression among participants in the BENEFIT (Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) clinical trial, a well-characterized cohort of >400 patients who were randomized to receive either interferon beta-1b (IFNb1b) or placebo soon after experiencing a clinically isolated syndrome (CIS).
Subjects and Methods

Study Population
The BENEFIT study was a clinical trial (NCT00185211) of 468 CIS patients who were randomized to receive either IFNb-1b or placebo within 60 days of the CIS, and were followed for conversion to MS (both clinically definite MS [CDMS] 9 and McDo-
nald MS [MDMS] 10
). The full details of the trial and results have been previously described. 11 Following conversion to CDMS or after 24 months, patients in the placebo group began treatment with IFNb-1b and patients were followed for an additional 3 years for a total of 5 years of follow-up. Expanded Disability Status Scale (EDSS) 12 was assessed and magnetic resonance imaging (MRI) was done at baseline, then every 3 months through month 12, and then at months 18, 24, 36, 48, and 60. EDSS scores were also assessed at months 30, 42, and 54. Relapses were confirmed as they occurred. At each clinic visit (baseline, every 3 months through month 12, and then every 6 months thereafter), patients provided casual ("spot") urine samples that were received by the central laboratory within 3 days of collection, and stored at 2208C. Samples were first thawed for assessment of urinary sodium and creatinine for this study. All participants in BENEFIT provided written informed consent, and this study was approved by the Office of Human Subjects Administration at the Harvard T. H. Chan School of Public Health and included only deidentified data and urine samples.
MRI
MRI procedures and processing used in BENEFIT have been previously described in full. 13 Briefly, T2-and T1-weighted images (following administration of 0.1mmol/kg of gadolinium-diethylenetriaminepentaacetic acid) were analyzed centrally at the Image Analysis Center at the VU University Medical Center in Amsterdam, where the number of new lesions (including active lesions) and lesion volume were determined.
Brain volumes were quantified using the SIENAX (structural image evaluation using normalization of atrophy cross-sectional) algorithm. 14 
Sodium Intake Assessment
As 80 to 90% of ingested sodium is excreted through urine, 15 we used urinary sodium as a marker of dietary sodium intake. Because sodium excretion varies throughout the day, 16 For this study, patients had a median of 14 urine samples collected (interquartile range 5 13-16 samples) between baseline and month 60, from which sodium and creatinine were measured. Urinary sodium and creatinine levels were quantified using a Roche/Hitachi Modular System (Roche Diagnostics, Indianapolis, IN), and patient height, weight, and age were documented as part of the existing clinical trial. In the initial laboratory assessment, estimated urinary creatinine levels were considerably lower than in previous global population-based studies. 16 Therefore, we reassessed creatinine levels in a subset of samples (n 5 96) and found the levels obtained in our initial assessments were likely underestimated. However, the initial and reassessment of creatinine were highly correlated (Spearman correlation 5 0.87), suggesting that although our estimates of absolute creatinine in the larger cohort may be underestimated, the relative ranking within the population is likely unaffected. We created "corrected" absolute creatinine value in the full study sample using the following calibration equation developed by regressing the initial estimates on the reassessed creatinine in the subset of 96 samples with both measurements: corrected creatinine; mg=dL536:8611:16 3ðinitial creatinine; mg=dLÞ These corrected estimates were then used to estimate 24-hour urinary sodium using the Tanaka equation shown above. 
Statistical Analysis
We treated estimated 24-hour urine sodium excretion as a time-dependent variable using at each time point the average of all previous values, and characterized the exposure in 3 a priori defined variables: (1) as continuous (grams per day), (2) dichotomized on the median (<3.7 vs !3.7g/day), and (3) as quintiles based on the overall distribution. For our primary analyses, we started follow-up at month 6, as baseline MRI measurements were obtained within 60 days of a clinical event and they could have been affected by underlying inflammatory processes. We analyzed time to conversion to MDMS and CDMS using Cox proportional hazards models and RR using an Andersen-Gill model to allow for repeated events. Other outcomes including cumulative number of new active lesions (CNAL), T2 lesion volume, brain volume, and EDSS scores were analyzed using generalized estimating equations. We modeled the number of CNAL as a count variable and the other outcomes as continuous variables. We conducted further analyses also using deciles and splines to explore the dose response. We adjusted each model for age, sex, randomization status (IFNb-1b vs placebo), type of CIS (monofocal vs multifocal), baseline T2 lesion score (the logarithm of the number of T2 lesions), body mass index (BMI; weight in kilograms/height in meters), and 25-hydroxyvitamin D status. We conducted several sensitivity analyses for each set of outcomes. First, we fit models using the average of all estimated 24-hour urinary sodium levels and assessed the association of non-time-varying estimated 24-hour sodium with MS outcomes (assuming variation in estimated 24-hour sodium is random). Next, we fit models using the average of estimated 24-hour urinary sodium during the first year (to relax the assumption that MS outcomes do not influence urinary sodium) and assessed its association with MS outcomes. Finally, we assessed the within-person change in estimated 24-hour urinary levels and its association with MS outcomes. Furthermore, we also conducted secondary analyses estimating 24-hour urinary sodium excretion using other similarly validated methods including using the ratio of sodium to creatinine 21 or adjustment equations developed by Kawasaki et al, 22 which, similar to the Tanaka equations, were developed in a Japanese population but have also similarly been extended to Western populations. 23 They include adjustments for age, height, weight, casual urinary sodium, and creatinine but are sex-specific. We also conducted sensitivity analyses restricted to casual urine samples collected in the midmorning (10:00 AM to 12:00 PM) as some studies have indicated these samples have a higher correlation with 24-hour urinary sodium levels. 24 
Results
Patient Characteristics and Estimated 24-Hour Sodium Levels
The median 24-hour urinary sodium excretion was 3.7g/ day, across all time points. Patients with higher 24-hour urinary sodium levels at month 6 were more likely to be male, had a higher BMI, and had fewer T2 lesions on baseline MRI (Table 1 ). Other patient characteristics including age, 25-hydroxyvitamin D level, CIS onset type, region of residence in Europe or Canada, and centralized brain volume did not appear to vary across estimated 24-hour urine sodium levels. In addition, overall estimated 24-hour urinary sodium was relatively consistent across time of day of sample collection and over the course of follow-up, but did display expected random day-to-day variation (Fig 1) .
Conversion to Definite MS
Starting follow-up at 6-months, 217 (75.0%) patients converted to MDMS and 150 (39%) patients converted to CDMS over the 5 years. We did not observe any association between higher levels (above the median or using quintiles) of estimated 24-hour sodium excretion and faster conversion rates after 6 months (median analyses: for CDMS, p 5 0.50; for MDMS, p 5 0.12; Fig 2A, (Table 2) . We observed similar results in analyses starting follow-up at month 12. In analyses using splines, we also did not detect any association between estimated 24-hour urine sodium levels and CIS to MS conversion (CDMS: p for any association 5 0.58; MDMS: p for any association 5 0.39).
Relapse and EDSS
We did not observe any association between estimated 24-hour urine sodium excretion and RR from month 6 to month 60 (see Fig 2E; per 1g increase in estimated 24-hour urine sodium excretion: relapse rate 5 0.86, 95% CI 5 0.71-1.05, p 5 0.14). Results were similar when considering estimated 24-hour sodium excretion and time to first relapse after conversion to definite MS (per 1g increase in estimated 24-hour urine sodium excretion: relapse rate 5 0.88, 95% CI 5 0.72-1.07, p 5 0.19). Similarly, we did not observe any associations between estimated 24-hour sodium excretion and confirmed changes in EDSS score from month 6 through month 60 (see Fig  2F; per 1g increase in estimated 24-hour sodium excretion: b 5 20.01, 95% CI 5 20.09 to 0.08, p 5 0.90).
MRI Estimated 24-hour urine sodium excretion was not associated with MRI activity. Levels were not associated with developing new lesions from month 6 to month 60 (per We conducted several sensitivity analyses that similarly did not indicate any association between estimated 24-hour urine sodium excretion and MS outcomes. First, we did not observe any association between non-timevarying estimated 24-hour urine sodium excretion (a metric that minimizes random variation in estimated excretion) and any MS outcome. Next, we did not observe any association between the average estimated 24-hour urine sodium excretion during the first year and subsequent MS outcomes. Finally, we did not observe any association between within-person changes in estimated 24-hour urine sodium excretion and MS outcomes. All of the above analyses were also conducted separately by randomized treatment group (placebo or IFNb-1b), and no associations between estimated 24-hour urine sodium excretion and any of the outcomes were observed. In addition, we repeated all analyses using the Kawasaki estimates for 24-hour urine sodium levels and the ratio of sodium to creatinine. As with the Tanaka estimate, we did not observe any associations between each additional sodium metric and MS outcomes.
Discussion
In this large, prospective study among patients with CIS and including a median of 14 urine sodium measurements per patient, estimated 24-hour urine sodium levels were not associated with conversion to definite MS (both FIGURE 1: (A, B) Estimated 24-hour urinary sodium excretion using the Tanaka equations by hour of sample collection (A) and by study visit (B). (C) Spaghetti plots of individual variability over follow-up in estimated 24-hour sodium excretion from selected study patients. Selected patients plotted are those having a patient-specific median excretion (across follow-up) at the 5th, 25th, 50th, 75th, and 95th percentiles of the distribution of patient-specific overall median values.
CDMS and MDMS) or with MS activity or early progression as indicated by both clinical and MRI outcomes over the 5 years of follow-up. One previous study was conducted among a population of 70 RRMS patients in Argentina and found that high levels of urinary sodium excretion (>4.8g/day) were associated with an increased RR and correlated with cross-sectional MRI activity. 8 In this study, the long-term average sodium intake-the hypothesized cause of MS exacerbations-was estimated from a single spot urine sample, which is a very poor proxy for long-term sodium excretion or intake. The error (ie, the difference between intake estimated from the single spot urine sample and the true long-term intake) is due mostly to random day-to-day within-person variations in sodium intake, and is thus unlikely to correlate with MS outcomes. As a result of such error, any hypothetical true association between actual sodium intake and MS outcomes would be strongly attenuated toward the null. Thus, the strong association reported by Farez et al would imply an even stronger association for true intake. 8 The results of our study with a larger sample size, multiple measurements, and diverse set of MS outcomes demonstrate that such strong association does not exist in the European and Canadian populations in BENEFIT. Thus, either the association reported in the Argentine study was a chance occurrence or it reflects an unknown mechanism unique to the population included in that study.
Our study is consistent with findings from a previous investigation of pediatric MS patients 7 that found no association between self-reported dietary sodium intake and time until relapse. However, in that study sodium intake was estimated using a food frequency questionnaire, which may be unreliable and underestimate intake of sodium. 25, 26 Furthermore, the questionnaire was administered only at baseline and thus could not account for changes in diet during the follow-up. For these reasons, it cannot be excluded that the null result was due to inadequate assessment of sodium intake.
Although the results of these epidemiological studies appear to be in conflict with EAE studies indicating an earlier and more aggressive disease course associated with high salt intake 4, 5 and in vitro observations that sodium chloride induces Th-17 generation 4,5 and IFNc secretion, 27 and causes a loss of Treg function, 27 changes that are expected to adversely affect the course of MS, the clinical relevance of these observation is uncertain. Among other considerations, it is uncertain whether high salt intake in humans can lead to sodium concentrations in the relevant fluid compartments that are comparable to those used in the in vitro experiments. Our study has several strengths, including its longitudinal design, nearly uniform treatment with INFb-1b, large sample size of nearly 500 patients with CIS, and systematic collection of both clinical and MRI data. Furthermore, the per-patient number of samples (median 5 14) in our study is considerably larger than in the previous report where 1 measure of 24-hour sodium excretion per patient was used. 8 Using formulas derived by Beaton et al 17 to calculate the number of samples needed to estimate a person's true 24-hour sodium levels with a specified degree of error, and assuming a coefficient of variation of 16% (as estimated in our samples), we estimate that 14 samples are sufficient to estimate 24-hour sodium levels to within 4% of their true mean 95% of the time.
Limitations include that BENEFIT participants were treated nearly uniformly with INFb-1b, and the results of our study may not apply to patients on other therapies. Although our results suggest there is no association between sodium intake and MS prognosis, they cannot comment as to whether sodium intake modifies risk of developing MS. In addition, patients in the BEN-EFIT trial were primarily Caucasian and resided in Europe and Canada, and it is currently unknown as to whether similarly null results would apply to other populations and ethnicities. The large number of samples (median 5 14 samples) contributed by each patient and the high ICC between average alternating samples lend credence to our analysis.
Taken together, these results suggest that high sodium intakes do not play a major role in influencing MS disease course or activity in patients treated with INFb-1b, at least in the early stages of disease. 
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